Pharmaceuticals

Lilly is a medicine company focused on turning science into healing. For 150 years, it has been pioneering life-changing discoveries, with medicines helping tens of millions globally. The company's scientists are advancing new discoveries in biotechnology, chemistry, and genetic medicine to address significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and cancer. Lilly aims to make life better for millions more people by delivering innovative clinical trials and ensuring accessible, affordable medicines.

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $5.5 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide.

Johnson & Johnson is a worldwide leader in multiple myeloma therapies. The company is advancing bispecific combinations earlier in the treatment journey, expanding options to match the right treatment to the right patient and stage of disease.

NurtureBio is a maternal and child wellness company applying breakthrough breast milk and microbiome research to early–life nutrition. Founded in 2024, the company develops synbiotic products that combine human milk oligosaccharides (HMOs) with targeted probiotic strains to support gut and immune health in infants and toddlers. Through active collaborations with leading academic researchers, including the University of Cincinnati College of Medicine, NurtureBio is advancing clinical studies on infant gut health and breast milk composition.

Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Building on this foundation, its purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease.

Cumberland Pharmaceuticals Inc. is a Nashville-based specialty pharmaceutical company focused on developing new therapies for rare diseases, advancing a clinical pipeline of investigational candidates.